BioNTech, compania din spatele vaccinului anti-COVID dezvoltat cu Pfizer, închide trei fabrici în Germania

BioNTech plans to close three facilities in Germany, affecting around 1,800 employees, as it shifts focus to cancer treatments. The closures in Tübingen, Marburg, and Idar-Oberstein are due to market conditions and excess production capacity. The company aims to transform into a multi-product biopharmaceutical firm by 2030, with oncology as a priority. BioNTech has seen a significant drop in COVID-19 vaccine demand, reporting a net loss of 1.35 billion euros in the first half of 2026. Efforts to streamline operations are expected to save around 500 million euros annually by 2029.